Cambridge, Massachusetts – Sept. 24, 2026 – City Therapeutics, a drug‑development company focused on innovative therapies, filed paperwork on Thursday to launch an initial public offering (IPO) in the United States. The company intends to list its shares on the Nasdaq exchange under the symbol “CTY.”
Underwriters and Offering Structure
The IPO will be managed by a consortium of leading investment banks: Goldman Sachs, Jefferies, Stifel and Oppenheimer. These underwriters will coordinate the sale of new shares to institutional and qualified individual investors, aiming to raise capital that will support City Therapeutics’ research pipeline and commercial expansion.
Company Background
Founded in Cambridge, City Therapeutics has built a reputation for developing novel treatments in areas such as oncology, rare diseases and immunology. The firm’s portfolio includes several candidates that have progressed to late‑stage clinical trials, positioning it for potential growth once publicly listed.
Strategic Rationale for Going Public
By accessing public markets, City Therapeutics seeks to secure the funding needed to accelerate its drug development programs, expand its manufacturing capabilities, and broaden its commercial reach. A Nasdaq listing also provides greater visibility among investors who are increasingly interested in biotech innovation.
Implications for the Biotechnology Sector
The filing adds to a recent wave of biotech IPOs, reflecting strong investor appetite for high‑impact medical research. Analysts note that the involvement of top-tier underwriters signals confidence in the company’s prospects and may encourage further capital inflows into the sector.
Next Steps
City Therapeutics will work with the Securities and Exchange Commission to finalize the prospectus and set a pricing range for the offering. Once the shares begin trading, the company will be subject to the reporting requirements and transparency standards of a publicly listed entity.
Investors and industry observers will watch closely as City Therapeutics moves toward its public debut, anticipating how the raised capital will translate into new therapeutic options for patients.
Original reporting: Appleton, WI News Feed (HLL/CB) — read the source article.
